Genoptix launches mutation analysis:
This article was originally published in Clinica
Carlsbad, California-based diagnostic specialist Genoptix has launched a test for a genetic mutation that is associated with a greater risk of blood cancers. The product tests patients for the MPL W515 L/K mutation, which affects the thrombopoietin receptor and results in the continuous activation of certain intracellular molecular pathways. It is associated with two myeloproliferative disorders: idiopathic myelofibrosis and essential thrombocythaemia. MPL W515 L/K mutation analysis may be particularly useful for patients with suspected MPD that are negative for JAK2 mutations, Genoptix said. The company believes it will be the first haematology/oncology laboratory service provider to offer this test.